{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:08:34Z","timestamp":1778749714786,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Subproject of the National Key Research and Development Program","award":["2021YFC2600263"],"award-info":[{"award-number":["2021YFC2600263"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873556"],"award-info":[{"award-number":["81873556"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"China Crohn\u2019s & Colitis Foundation","award":["CCCF-QF-2022B67-3"],"award-info":[{"award-number":["CCCF-QF-2022B67-3"]}]},{"name":"Beijing Research Association for Chronic Diseases Control and Health Education","award":["MBZX0162024001"],"award-info":[{"award-number":["MBZX0162024001"]}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.17397"],"award-info":[{"award-number":["320.6750.17397"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02098-z","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:40:19Z","timestamp":1771994419000},"page":"1015-1025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral low-dose methotrexate improves infliximab pharmacokinetics, immunogenicity, and endoscopic outcomes in Crohn\u2019s disease: a propensity score-adjusted real-world study"],"prefix":"10.1007","volume":"48","author":[{"given":"Shangzhan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runzhao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinxian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qionghui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anqi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiazhi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2098_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz180","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis"},{"key":"2098_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1324-3","author":"Y Qiu","year":"2017","unstructured":"Qiu Y, Chen BL, Mao R, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease. J Gastroenterol. 2017. https:\/\/doi.org\/10.1007\/s00535-017-1324-3.","journal-title":"J Gastroenterol"},{"key":"2098_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.363","author":"KS Nanda","year":"2013","unstructured":"Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013. https:\/\/doi.org\/10.1038\/ajg.2012.363.","journal-title":"Am J Gastroenterol"},{"key":"2098_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16605","author":"JPD Schultheiss","year":"2021","unstructured":"Schultheiss JPD, Mahmoud R, Louwers JM, et al. Loss of response to anti-TNF\u03b1 agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2021. https:\/\/doi.org\/10.1111\/apt.16605.","journal-title":"Aliment Pharmacol Ther"},{"key":"2098_CR5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i15.2068","author":"JK Triantafillidis","year":"2024","unstructured":"Triantafillidis JK, Zografos CG, Konstadoulakis MM, et al. Combination treatment of inflammatory bowel disease: present status and future perspectives. World J Gastroenterol. 2024. https:\/\/doi.org\/10.3748\/wjg.v30.i15.2068.","journal-title":"World J Gastroenterol"},{"key":"2098_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010. https:\/\/doi.org\/10.1056\/NEJMoa0904492.","journal-title":"N Engl J Med"},{"key":"2098_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.049460","author":"A Kandiel","year":"2005","unstructured":"Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005. https:\/\/doi.org\/10.1136\/gut.2004.049460.","journal-title":"Gut"},{"key":"2098_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000274","author":"HT Kim","year":"2017","unstructured":"Kim HT, Choi R, Won HH, et al. NUDT15 genotype distributions in the Korean population. Pharmacogenet Genomics. 2017. https:\/\/doi.org\/10.1097\/FPC.0000000000000274.","journal-title":"Pharmacogenet Genomics"},{"key":"2098_CR9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.024","author":"BG Feagan","year":"2014","unstructured":"Feagan BG, McDonald JWD, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease. Gastroenterology. 2014. https:\/\/doi.org\/10.1053\/j.gastro.2013.11.024.","journal-title":"Gastroenterology"},{"key":"2098_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-023-01116-7","author":"E Vermeer","year":"2023","unstructured":"Vermeer E, Hebing RCF, van de Meeberg MM, et al. Oral versus subcutaneous methotrexate in immune-mediated inflammatory disorders: an update of the current literature. Curr Rheumatol Rep. 2023. https:\/\/doi.org\/10.1007\/s11926-023-01116-7.","journal-title":"Curr Rheumatol Rep"},{"key":"2098_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.525","author":"R Hebing","year":"2021","unstructured":"Hebing R, Muller I, Lin M, et al. Increased accumulation of erythrocyte methotrexate polyglutamates during early phase subcutaneous versus oral methotrexate treatment of rheumatoid arthritis patients. Ann Rheum Dis. 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.525.","journal-title":"Ann Rheum Dis"},{"key":"2098_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08237-0","author":"J Park","year":"2024","unstructured":"Park J, Chun J, Park SJ, et al. Effectiveness and tolerability of methotrexate combined with biologics in patients with Crohn\u2019s disease: a multicenter observational study. Dig Dis Sci. 2024. https:\/\/doi.org\/10.1007\/s10620-023-08237-0.","journal-title":"Dig Dis Sci"},{"key":"2098_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134382","author":"K Demase","year":"2023","unstructured":"Demase K, Monitto CK, Little RD, et al. The role of low-dose oral methotrexate in increasing anti-TNF drug levels and reducing immunogenicity in IBD. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12134382.","journal-title":"J Clin Med"},{"key":"2098_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221085889","author":"A Cassinotti","year":"2022","unstructured":"Cassinotti A, Batticciotto A, Parravicini M, et al. Evidence-based efficacy of methotrexate in adult Crohn\u2019s disease in different intestinal and extraintestinal indications. Ther Adv Gastroenterol. 2022. https:\/\/doi.org\/10.1177\/17562848221085889.","journal-title":"Ther Adv Gastroenterol"},{"key":"2098_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.774824","author":"Y Wang","year":"2021","unstructured":"Wang Y, Li Y, Liu Y, et al. Patients with IBD receiving methotrexate are at higher risk of liver injury compared with patients with non-IBD diseases: a meta-analysis and systematic review. Front Med (Lausanne). 2021. https:\/\/doi.org\/10.3389\/fmed.2021.774824.","journal-title":"Front Med (Lausanne)"},{"key":"2098_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy010","author":"LY Chi","year":"2018","unstructured":"Chi LY, Zitomersky NL, Liu E, et al. The impact of combination therapy on infliximab levels and antibodies in children and young adults with inflammatory bowel disease. Inflamm Bowel Dis. 2018. https:\/\/doi.org\/10.1093\/ibd\/izy010.","journal-title":"Inflamm Bowel Dis"},{"key":"2098_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz020","author":"NZ Borren","year":"2019","unstructured":"Borren NZ, Luther J, Colizzo FP, et al. Low-dose methotrexate has similar outcomes to high-dose methotrexate in combination with anti-TNF therapy in inflammatory bowel diseases. J Crohns Colitis. 2019. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz020.","journal-title":"J Crohns Colitis"},{"key":"2098_CR18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.011","author":"GS Hazlewood","year":"2015","unstructured":"Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis. Gastroenterology. 2015. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.011.","journal-title":"Gastroenterology"},{"key":"2098_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2023-001246","author":"Y Gonz\u00e1lez-Lama","year":"2024","unstructured":"Gonz\u00e1lez-Lama Y, Ricart E, Carpio D, et al. Controversies in the management of anti-TNF therapy in patients with Crohn\u2019s disease: a Delphi consensus. BMJ Open Gastroenterol. 2024. https:\/\/doi.org\/10.1136\/bmjgast-2023-001246.","journal-title":"BMJ Open Gastroenterol"},{"key":"2098_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.08.006","author":"MD Wewer","year":"2025","unstructured":"Wewer MD, Letnar G, Andersen KK, et al. Thiopurines and the risk of cancer in patients with inflammatory bowel disease and reference individuals without inflammatory bowel disease: a Danish nationwide cohort study (1996\u20132018). Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2024.08.006.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2098_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.784712","author":"K Khaeso","year":"2021","unstructured":"Khaeso K, Udayachalerm S, Komvilaisak P, et al. Meta-analysis of NUDT15 genetic polymorphism on thiopurine-induced myelosuppression in Asian populations. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.784712.","journal-title":"Front Pharmacol"},{"key":"2098_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3508","author":"T Moriyama","year":"2016","unstructured":"Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016. https:\/\/doi.org\/10.1038\/ng.3508.","journal-title":"Nat Genet"},{"key":"2098_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae091","author":"H Gordon","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2024. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae091.","journal-title":"J Crohns Colitis"},{"key":"2098_CR24","doi-asserted-by":"publisher","unstructured":"Arieira C, de Dias Castro F, C\u00fardia Gon\u00e7alves T, et al. Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine? Scand J Gastroenterol. 2020. https:\/\/doi.org\/10.1080\/00365521.2020.1792543.","DOI":"10.1080\/00365521.2020.1792543"},{"key":"2098_CR25","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2022.0766","author":"A Nawaz","year":"2023","unstructured":"Nawaz A, Glick LR, Chaar A, et al. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Ann Gastroenterol. 2023. https:\/\/doi.org\/10.20524\/aog.2022.0766.","journal-title":"Ann Gastroenterol"},{"key":"2098_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204769","author":"GR Burmester","year":"2015","unstructured":"Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204769.","journal-title":"Ann Rheum Dis"},{"key":"2098_CR27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"key":"2098_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae159","author":"BE Sands","year":"2025","unstructured":"Sands BE, Danese S, Chapman JC, et al. Mucosal and transmural healing and long-term outcomes in Crohn\u2019s disease. Inflamm Bowel Dis. 2025. https:\/\/doi.org\/10.1093\/ibd\/izae159.","journal-title":"Inflamm Bowel Dis"},{"key":"2098_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae128","author":"R Panaccione","year":"2024","unstructured":"Panaccione R, Ma C, Jairath V, et al. Achievement of endoscopic remission after induction reduces hospitalization burden in Crohn\u2019s disease: findings from a pooled post hoc analysis of risankizumab and upadacitinib phase III trials. J Crohns Colitis. 2024. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae128.","journal-title":"J Crohns Colitis"},{"key":"2098_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309598","author":"RV Bryant","year":"2016","unstructured":"Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in ulcerative colitis: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016. https:\/\/doi.org\/10.1136\/gutjnl-2015-309598.","journal-title":"Gut"},{"key":"2098_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15447","author":"A Husam Al-Ani","year":"2021","unstructured":"Husam Al-Ani A, Christensen B. Endoscopic and histologic endpoints as treatment targets: are we there yet? J Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1111\/jgh.15447.","journal-title":"J Gastroenterol Hepatol"},{"key":"2098_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21925","author":"JE Baars","year":"2012","unstructured":"Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012. https:\/\/doi.org\/10.1002\/ibd.21925.","journal-title":"Inflamm Bowel Dis"},{"key":"2098_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304984","author":"L Peyrin-Biroulet","year":"2014","unstructured":"Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn\u2019s disease in the SONIC trial. Gut. 2014. https:\/\/doi.org\/10.1136\/gutjnl-2013-304984.","journal-title":"Gut"},{"key":"2098_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099978","author":"S Vermeire","year":"2007","unstructured":"Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease. Gut. 2007. https:\/\/doi.org\/10.1136\/gut.2006.099978.","journal-title":"Gut"},{"key":"2098_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.10.016","author":"AJ Yarur","year":"2023","unstructured":"Yarur AJ, McGovern D, Abreu MT, et al. Combination therapy with immunomodulators improves the pharmacokinetics of infliximab but not vedolizumab or ustekinumab. Clin Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.cgh.2022.10.016.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2098_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.10.025","author":"B Ungar","year":"2016","unstructured":"Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016. https:\/\/doi.org\/10.1016\/j.cgh.2015.10.025.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2098_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.11.014","author":"K Papamichael","year":"2016","unstructured":"Papamichael K, Van Stappen T, Vande Casteele N, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016. https:\/\/doi.org\/10.1016\/j.cgh.2015.11.014.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2098_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.09.031","author":"W Reinisch","year":"2015","unstructured":"Reinisch W, Colombel JF, Sandborn WJ, et al. Factors associated with short- and long-term outcomes of therapy for Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2015. https:\/\/doi.org\/10.1016\/j.cgh.2014.09.031.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2098_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1192827","author":"SY Choi","year":"2023","unstructured":"Choi SY, Kwon Y, Choi S, et al. Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn\u2019s disease. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1192827.","journal-title":"Front Immunol"},{"key":"2098_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0829-7","author":"H Imaeda","year":"2014","unstructured":"Imaeda H, Bamba S, Takahashi K, et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn\u2019s disease under scheduled maintenance treatment. J Gastroenterol. 2014. https:\/\/doi.org\/10.1007\/s00535-013-0829-7.","journal-title":"J Gastroenterol"},{"key":"2098_CR41","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.03.224","author":"MD Kappelman","year":"2023","unstructured":"Kappelman MD, Wohl DA, Herfarth HH, et al. Comparative effectiveness of anti-TNF in combination with low-dose methotrexate vs anti-TNF monotherapy in pediatric Crohn\u2019s disease: a pragmatic randomized trial. Gastroenterology. 2023. https:\/\/doi.org\/10.1053\/j.gastro.2023.03.224.","journal-title":"Gastroenterology"},{"key":"2098_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.07.011","author":"MB Sprakes","year":"2012","unstructured":"Sprakes MB, Ford AC, Warren L, et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn\u2019s disease: a large single centre experience. J Crohns Colitis. 2012. https:\/\/doi.org\/10.1016\/j.crohns.2011.07.011.","journal-title":"J Crohns Colitis"},{"key":"2098_CR43","doi-asserted-by":"publisher","unstructured":"Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: results from a single-centre cohort. Gut. 2009. https:\/\/doi.org\/10.1136\/gut.2008.155812.","DOI":"10.1136\/gut.2008.155812"},{"key":"2098_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.04.010","author":"V Grossi","year":"2015","unstructured":"Grossi V, Lerer T, Griffiths A, et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2015. https:\/\/doi.org\/10.1016\/j.cgh.2015.04.010.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2098_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30012-3","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicenter, cohort study. Lancet Gastroenterol Hepatol. 2019. https:\/\/doi.org\/10.1016\/S2468-1253(19)30012-3.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02098-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02098-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02098-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:16:01Z","timestamp":1778746561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02098-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2098"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02098-z","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval No. TJ-IRB202506001).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patient consent was waived due to the retrospective nature of the study and anonymization of all clinical data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}